Used in targeted cancer therapy, particularly for tumors with c-Met receptor overexpression or dysregulation. It blocks hepatocyte growth factor (HGF) binding and inhibits c-Met signaling, which is involved in tumor growth, survival, and metastasis. Investigated in clinical trials for non-small cell lung cancer, gastric cancer, and other solid tumors. Enables precise targeting of cancer cells while sparing normal tissues, supporting development of personalized treatment strategies. Also serves as a reference standard in immunoassay development and antibody drug characterization.